EUVIMEDEUVIMED entdecken
Crossref

α‐Lipoic Acid‐Based Nanozyme for Treating Acute Epilepsy

Yage Sun, Xinrui Zhao, Rong Yang, Meng Xiao, Wenguang Liu

Advanced Functional Materials · 2025-01 · 35 (3)

DOI: 10.1002/adfm.202412633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 11.12.2024. Verfasst von Yage Sun und 4 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Key Research and Development Program of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti‐epilepsy drugs (AEDs), a common therapeutic approach for clinically treating epilepsy, suffer from low permeability toward the blood‐brain barrier (BBB), side effect risks, and a failure to regulate the pathological microenvironment. These issues hinder the complete control of epilepsy and lead to a vicious cycle of inflammation‐epileptogenesis. Herein, an α‐lipoic acid (LA)‐based nanozyme that loads phenytoin (PHT) and complexes calcium ions (LA@PHT‐Ca 2+ ) is developed. This nanozyme combines the functions of delivering AEDs across the BBB and regulating undesirable microenvironments to treat epilepsy. Amphipathic LA self‐assembles into stable nanoparticles in water with BBB crossing ability endowed by the transporting of LA through sodium‐dependent multivitamin transporter. LA's enzyme‐like and redox functions provide LA@PHT‐Ca 2+ with excellent scavenging effects on several free radicals via cascade reactions, thereby protecting neurons from oxidative stress. Moreover, Ca 2+ disrupts neuronal respiration, resulting in reduced production of bioenergetic adenosine triphosphate and an improved hypoxic microenvironment. This leads to decreased expression of P‐glycoprotein, a drug‐efflux gating protein. This novel lipoic acid‐based nanozyme, with intrinsic BBB crossing capability, prolonged intracellular drug retention time, and the ability to block the inflammation‐epileptogenesis cycle, presents a satisfactory therapeutic effect in epileptic rats, resulting in attenuated symptoms and an improved microenvironment.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Sun, Y., Zhao, X., Yang, R., Xiao, M., & Liu, W. (2025). α‐Lipoic Acid‐Based Nanozyme for Treating Acute Epilepsy. Advanced Functional Materials, 35(3). https://doi.org/10.1002/adfm.202412633

Vancouver

Sun Y, Zhao X, Yang R, Xiao M, Liu W. α‐Lipoic Acid‐Based Nanozyme for Treating Acute Epilepsy. Advanced Functional Materials. 2025;35(3). doi:10.1002/adfm.202412633

BibTeX
@article{Sun2025,
  author = {Sun, Yage and Zhao, Xinrui and Yang, Rong and Xiao, Meng and Liu, Wenguang},
  title = {α‐Lipoic Acid‐Based Nanozyme for Treating Acute Epilepsy},
  journal = {Advanced Functional Materials},
  year = {2025},
  volume = {35},
  number = {3},
  doi = {10.1002/adfm.202412633}
}
Kostenlos starten →